252 related articles for article (PubMed ID: 17091764)
1. Critical roles of glutamine as nitrogen donors in purine and pyrimidine nucleotide synthesis: asparaginase treatment in childhood acute lymphoblastic leukemia.
Cory JG; Cory AH
In Vivo; 2006; 20(5):587-9. PubMed ID: 17091764
[TBL] [Abstract][Full Text] [Related]
2. An isocratic fluorescence HPLC assay for the monitoring of l-asparaginase activity and l-asparagine depletion in children receiving E. colil-asparaginase for the treatment of acute lymphoblastic leukaemia.
Nath CE; Dallapozza L; Eslick AE; Misra A; Carr D; Earl JW
Biomed Chromatogr; 2009 Feb; 23(2):152-9. PubMed ID: 18823071
[TBL] [Abstract][Full Text] [Related]
3. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia.
Earl M
Clin Adv Hematol Oncol; 2009 Sep; 7(9):600-6. PubMed ID: 20020672
[TBL] [Abstract][Full Text] [Related]
4. Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia?
Douer D
Best Pract Res Clin Haematol; 2008 Dec; 21(4):647-58. PubMed ID: 19041604
[TBL] [Abstract][Full Text] [Related]
5. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961).
Panosyan EH; Grigoryan RS; Avramis IA; Seibel NL; Gaynon PS; Siegel SE; Fingert HJ; Avramis VI
Anticancer Res; 2004; 24(2C):1121-5. PubMed ID: 15154634
[TBL] [Abstract][Full Text] [Related]
6. Use of L-asparaginase in acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group.
Piatkowska-Jakubas B; Krawczyk-Kuliś M; Giebel S; Adamczyk-Cioch M; Czyz A; Lech Marańda E; Paluszewska M; Pałynyczko G; Piszcz J; Hołowiecki J;
Pol Arch Med Wewn; 2008 Nov; 118(11):664-9. PubMed ID: 19140571
[TBL] [Abstract][Full Text] [Related]
7. No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy.
Tong WH; Pieters R; Hop WC; Lanvers-Kaminsky C; Boos J; van der Sluis IM
Pediatr Blood Cancer; 2013 Feb; 60(2):258-61. PubMed ID: 22961784
[TBL] [Abstract][Full Text] [Related]
8. Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961).
Grigoryan RS; Panosyan EH; Seibel NL; Gaynon PS; Avramis IA; Avramis VI
In Vivo; 2004; 18(2):107-12. PubMed ID: 15113036
[TBL] [Abstract][Full Text] [Related]
9. L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.
Top PC; Tissing WJ; Kuiper JW; Pieters R; van Eijck CH
Pediatr Blood Cancer; 2005 Jan; 44(1):95-7. PubMed ID: 15368548
[TBL] [Abstract][Full Text] [Related]
10. The best way to use asparaginase in childhood acute lymphatic leukaemia--still to be defined?
Pinheiro JP; Boos J
Br J Haematol; 2004 Apr; 125(2):117-27. PubMed ID: 15059133
[No Abstract] [Full Text] [Related]
11. Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukemia.
Steiner M; Attarbaschi A; Kastner U; Dworzak M; Haas OA; Gadner H; Mann G
Pediatr Blood Cancer; 2007 Oct; 49(5):640-2. PubMed ID: 16941647
[TBL] [Abstract][Full Text] [Related]
12. L-asparaginase-induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children.
Hourani R; Abboud M; Hourani M; Khalifeh H; Muwakkit S
Neuropediatrics; 2008 Feb; 39(1):46-50. PubMed ID: 18504683
[TBL] [Abstract][Full Text] [Related]
13. Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia.
Beinart G; Damon L
Am J Hematol; 2004 Dec; 77(4):331-5. PubMed ID: 15551293
[TBL] [Abstract][Full Text] [Related]
14. Management of L-asparaginase induced prothrombotic state in acute lymphoblastic leukemia.
Parma M; Belotti D; Pogliani EM
Haematologica; 1996; 81(2):191. PubMed ID: 8641657
[No Abstract] [Full Text] [Related]
15. Transient hyperthyroidism following L-asparaginase therapy for acute lymphoblastic leukemia.
Fadilah SA; Faridah I; Cheong SK
Med J Malaysia; 2000 Dec; 55(4):513-5. PubMed ID: 11221167
[TBL] [Abstract][Full Text] [Related]
16. Asparaginase in the treatment of non-ALL hematologic malignancies.
Emadi A; Zokaee H; Sausville EA
Cancer Chemother Pharmacol; 2014 May; 73(5):875-83. PubMed ID: 24515335
[TBL] [Abstract][Full Text] [Related]
17. Monolith and coating enzymatic microreactors of L-asparaginase: kinetics study by MCE-LIF for potential application in acute lymphoblastic leukemia (ALL) treatment.
Qiao J; Qi L; Mu X; Chen Y
Analyst; 2011 May; 136(10):2077-83. PubMed ID: 21461410
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic bone marrow transplantation after L-asparaginase-induced pancreatitis in a patient with acute lymphoblastic leukemia.
Yamada Y; Ito K; Watanabe Y; Nosaka K; Horikawa K; Hidaka M; Kawano F; Sasaki Y; Mitsuya H; Asou N
Leuk Res; 2008 Dec; 32(12):1944-6. PubMed ID: 18502503
[No Abstract] [Full Text] [Related]
19. L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.
Tsurusawa M; Chin M; Iwai A; Nomura K; Maeba H; Taga T; Higa T; Kuno T; Hori T; Muto A; Yamagata M;
Cancer Chemother Pharmacol; 2004 Mar; 53(3):204-8. PubMed ID: 14634792
[TBL] [Abstract][Full Text] [Related]
20. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.
Hunault-Berger M; Chevallier P; Delain M; Bulabois CE; Bologna S; Bernard M; Lafon I; Cornillon J; Maakaroun A; Tizon A; Padrazzi B; Ifrah N; Gruel Y;
Haematologica; 2008 Oct; 93(10):1488-94. PubMed ID: 18728028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]